Treg Resistance Detection via PGC-1α Biomarker Profiling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to distinguish between defective and Treg-resistant T-cells in patients with autoimmunity, as both populations share similar activation markers and cytokine profiles, complicating the diagnosis and treatment of autoimmune diseases like multiple sclerosis.
Innovation Solution
The detection of impaired responsiveness of CD4+ T-cells to regulatory T-cells (Treg) is achieved by measuring the expression levels of PPARGC1A and other upstream regulators, which are associated with Treg resistance, allowing for the identification of biomarkers that differentiate between Treg-sensitive and Treg-resistant cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional methods measure activation markers and cytokine profiles to identify T-cell dysfunction, then general immune status can be assessed, but the ability to distinguish between defective and Treg-resistant T-cells is lost
Solution Approach 1:
The patent extracts and measures specific molecules (IL-6, sIL-6R, IL-10) from the complex T-cell system to differentiate between defective and Treg-resistant T-cells. By focusing on these specific extracted markers rather than general activation markers, the method achieves precise differentiation without requiring complex multi-parameter analysis of all possible T-cell markers.
Solution Approach 2:
The patent uses IL-6, sIL-6R, and IL-10 as intermediary molecules that mediate the distinction between defective and Treg-resistant T-cells. These intermediary markers serve as proxies that translate the complex functional differences between cell populations into measurable molecular signatures, enabling differentiation without direct observation of functional behavior.
2Measurement precision
If Treg-mediated suppression is impaired in autoimmune diseases, then diagnostic accuracy improves, but treatment response becomes heterogeneous and difficult to predict
Solution Approach 1:
The patent establishes a feedback mechanism where measurement of IL-6, sIL-6R, and IL-10 levels provides information about Treg resistance status, which then guides treatment selection and monitoring. This feedback loop enables prediction of treatment response based on baseline molecular profiles, reducing heterogeneity in treatment outcomes by matching patients to appropriate therapies based on their Treg resistance characteristics.
3Loss of time
If early detection of autoimmune diseases is achieved through Treg resistance markers, then therapeutic intervention timing improves, but detection method complexity increases
Solution Approach 1:
The patent segments the detection process into distinct molecular targets (IL-6, sIL-6R, IL-10) that can be measured independently. This segmentation allows for early detection through focused measurement of specific markers rather than comprehensive immune profiling, reducing the complexity burden while maintaining early detection capability. The segmented approach enables modular implementation where not all markers need to be measured in every case.
Data Source
AI summary
A method for the detection of impaired responsiveness of CD4+ T-cells to regulatory T-cells (Treg), Treg resistance, by measuring the expression levels of peroxisome proliferator-activated receptor gamma coactivator 1-alpha, PPARGC1A (PGC-1α) in activated CD4+ T-cells, in particular in patients suffering from relapsing remitting multiple sclerosis. The invention relates to an in vitro screening method for the detection of an autoimmune disease or a condition, comprising the steps of generating a functional gene expression profile by measuring the expression levels of peroxisome proliferator-activated receptor gamma coactivator 1-alpha, PPARGC1A (PGC-1α) in Treg-resistant CD4+ T-cells from patients suffering of an autoimmune disease or condition, and comparing the obtained gene expression profile with the expression profile from Treg-sensitive CD4+ T-cells from healthy controls. PCG-1α or an upstream regulator of Treg-resistant T-cells HNF4A, Hdac, RORA, ESRRA, LPIN1 can be used in a screening system for the detection of impaired responsiveness of CD4+ T-cells to Treg.